Efficacy News and Research

RSS

Three-drug regimen taken during pregnancy prevents mother-to-child HIV transmission

For HIV-infected women in good immune health, taking a three-drug regimen during pregnancy prevents mother-to-child HIV transmission more effectively than taking one drug during pregnancy, another during labor and two more after giving birth, an international clinical trial has found.

19 Nov 2014

Omega-3 benefits may be sustained in early psychosis

The positive effects of omega-3 supplementation seen in patients at high risk of psychosis in a previous randomised, controlled trial may be sustained, the investigators reported at the International Early Psychosis Conference in Tokyo, Japan.

19 Nov 2014

Strict monitoring of lithium levels urged

Plasma levels of lithium above the advised range are associated with a transient reduction in kidney function, research shows.

19 Nov 2014

Janssen announces submission of NDA for three-month paliperidone palmitate

Janssen Research & Development, LLC today announced the submission of a New Drug Application (NDA) for three-month atypical antipsychotic paliperidone palmitate to the U.S. Food and Drug Administration. The NDA seeks approval for the medication as a treatment for schizophrenia in adults.

19 Nov 2014

Common anti-malaria medicine could have significant impact on colorectal cancer

Medical experts say a common malaria drug could have a significant impact on colorectal cancer providing a cheap adjunct to current expensive chemotherapy.

18 Nov 2014

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with PharmAbcine, Inc. for the development, manufacturing and marketing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and several emerging countries, including Thailand, Brazil and Russia.

18 Nov 2014

Three-day global symposium on Ebola virus, other infectious diseases

The 11th annual International Consortium on Anti-Virals (ICAV) symposium, Infectious Diseases: Global Public-Health Challenges of the Next Decade, will put the challenges posed by several infectious diseases under the microscope, including the Ebola virus, the H7N9 influenza virus, MERS coronavirus and dengue viruses, as well as drug-resistant tuberculosis.

18 Nov 2014

Zytiga is commonly prescribed for second-line treatment of mCRPC patients

Decision Resources Group finds that Johnson & Johnson/Janssen Biotech/Janssen Cilag/AstraZeneca's Zytiga is the clear agent of choice for second-line treatment of metastatic castrate-resistant prostate cancer (mCRPC) patients, according to surveyed oncologists from France, Germany, Italy, Spain, and the United Kingdom (EU5).

18 Nov 2014

New oral medication shows promise in treating fibromyalgia

A new oral medication known as IMC-1, developed by Innovative Med Concepts, proved highly effective at reducing pain and other symptoms of fibromyalgia (FM) in patients in a recent clinical trial.

18 Nov 2014

IntelliCap electronic oral drug delivery technology wins prestigious European ‘High-Tech Innovation Award’

The IntelliCap electronic oral drug delivery technology, created by medtech innovator Medimetrics, has won a prestigious European ‘High-Tech Innovation Award’ from Accenture, the global management consultancy.

18 Nov 2014

Pros and cons of medical marijuana to be discussed at Queensland Epilepsy Symposium

The pros and cons of medical marijuana is a discussion focus at the fifth annual Queensland Epilepsy Symposium, Epilepsy – On the Horizon.

18 Nov 2014

Prana's Phase 2 trial data on Huntington Disease published in The Lancet Neurology

Prana Biotechnology has today announced the results of its Phase 2 trial in Huntington Disease, REACH2HD, has been published online in one of the world’s leading medical journals, The Lancet Neurology.

18 Nov 2014

Study evaluates efficacy, safety of zirconium cyclosilicate drug in patients with hyperkalemia

Mikhail Kosiborod, M.D., of Saint Luke's Mid America Heart Institute, Kansas City, and colleagues evaluated the efficacy and safety of the drug zirconium cyclosilicate in patients with hyperkalemia (higher than normal potassium levels). The study appears in JAMA and is being released to coincide with its presentation at the American Heart Association's Scientific Sessions 2014.

18 Nov 2014

Adding ezetimibe to statin therapy reduces cardiovascular events

More than a decade ago, researchers from Brigham and Women's Hospital demonstrated that a high dose statin, which lowered cholesterol further than a regular dose statin, provided better clinical outcomes. But questions remained about whether further reducing cholesterol would be even more effective in reducing cardiovascular-related events.

18 Nov 2014

ZS Pharma reports positive ZS-9 Phase 3 clinical trial for treatment of hyperkalemia

ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today presented detailed results from HARMONIZE (ZS004) at the late-breaking Clinical Science Special Reports Session of the American Heart Association Scientific Sessions.

18 Nov 2014

Beckman Coulter Life Sciences contributes its flow cytometry expertise to support the ONE Study

Beckman Coulter Life Sciences participates in the ONE Study, international collaboration of scientists across Europe and the USA.

From Beckman Coulter Life Sciences - Flow Cytometry 17 Nov 2014

Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing forms of MS

Sanofi and its subsidiary Genzyme announced today that the U.S. Food and Drug Administration has approved Lemtrada (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Lemtrada should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

17 Nov 2014

Lobectomy outweighs sublobar resection for elderly early-stage NSCLC patients

Lobectomy may the best option for elderly patients with early-stage non-small-cell lung cancer who are able to undergo surgery, say researchers from the US.

14 Nov 2014

Rare gene mutation linked to lower cholesterol levels, reduced risk of heart attack

Rare mutations that shut down a single gene are linked to lower cholesterol levels and a 50 percent reduction in the risk of heart attack, according to new research from Washington University School of Medicine in St. Louis, the Broad Institute at Massachusetts Institute of Technology and Harvard, and other institutions.

14 Nov 2014

Concordia Healthcare reports record revenues of 147% in third quarter 2014

Concordia Healthcare Corp. ("Concordia" or the "Company"), a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced its financial and operational results for the three and nine months ended September 30, 2014.

14 Nov 2014

Efficacy News and Research

Three-drug regimen taken during pregnancy prevents mother-to-child HIV transmission

Omega-3 benefits may be sustained in early psychosis

Strict monitoring of lithium levels urged

Janssen announces submission of NDA for three-month paliperidone palmitate

Common anti-malaria medicine could have significant impact on colorectal cancer

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

Three-day global symposium on Ebola virus, other infectious diseases

Zytiga is commonly prescribed for second-line treatment of mCRPC patients

New oral medication shows promise in treating fibromyalgia

IntelliCap electronic oral drug delivery technology wins prestigious European ‘High-Tech Innovation Award’

Pros and cons of medical marijuana to be discussed at Queensland Epilepsy Symposium

Prana's Phase 2 trial data on Huntington Disease published in The Lancet Neurology

Study evaluates efficacy, safety of zirconium cyclosilicate drug in patients with hyperkalemia

Adding ezetimibe to statin therapy reduces cardiovascular events

ZS Pharma reports positive ZS-9 Phase 3 clinical trial for treatment of hyperkalemia

Beckman Coulter Life Sciences contributes its flow cytometry expertise to support the ONE Study

Sanofi, Genzyme announce FDA approval of Lemtrada for treatment of relapsing forms of MS

Lobectomy outweighs sublobar resection for elderly early-stage NSCLC patients

Rare gene mutation linked to lower cholesterol levels, reduced risk of heart attack

Concordia Healthcare reports record revenues of 147% in third quarter 2014

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News